We develop transformative antibody therapeutics for patients, with a current focus on oncology, inflammatory diseases, and immunology.
We match disease biology and therapeutic targets with next-generation antibody formats and design challenges into blueprints for safer and more effective medicines.
Advancing a pipeline of therapeutics towards the clinic
Modality
Therapeutic area
Stage of development
Owner
Therapeutic area
Next-gen ADC
Modality
Solid Cancers
Stage of development
Discovery
Clinic
Therapeutic area
Next-gen T cell engager
Modality
Solid Cancers
Stage of development
Discovery
Clinic
Therapeutic area
IgG antagonist
Modality
Inflammatory Disease
Stage of development
Discovery
Clinic
Therapeutic area
Next-gen ADC
Modality
Solid Cancers
Stage of development
Discovery
Clinic
Therapeutic area
VHH
Modality
Half-life Extension
Stage of development
Discovery
Clinic
Therapeutic area
VHH
Modality
Not Disclosed
Stage of development
Discovery
Clinic
Therapeutic area
Not Disclosed
Modality
Not Disclosed
Stage of development
Discovery
Clinic
PARTNER
Partner with us
BigHat engages with strategic partners to tackle complex protein therapeutic design challenges.
